Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer

European Urology

Volumn 67, Issue 6, 2015, Pages 993-1005

  Simpkin, Andrew J ^a   Tilling, Kate ^a   Martin, Richard M ^a,b   Lane, J Athene ^a   Hamdy, Freddie C ^c   Holmberg, Lars ^d   Neal, David E ^e   Metcalfe, Chris ^a   Donovan, Jenny L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Active monitoring; Active surveillance; Conservative management; Deferred treatment; Expectant management; Localized prostate cancer; Meta analysis; Prostatic neoplasms; Systematic review; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER LOCALIZATION; CANCER MORTALITY; CANCER THERAPY; CLINICAL PROTOCOL; COHORT ANALYSIS; DISEASE SURVEILLANCE; EMBASE; FOLLOW UP; GLEASON SCORE; HUMAN; LOW RISK PATIENT; MALE; MEDLINE; META ANALYSIS; METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; TUMOR BIOPSY; WEB OF SCIENCE; BIOPSY; BLOOD; CANCER GRADING; DISEASE COURSE; MORTALITY; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTOR; WATCHFUL WAITING;

BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; WATCHFUL WAITING;

EID: 84929025473     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.01.004     Document Type: Review

References (49)

1. R. Choo, L. Klotz, and C. Danjoux Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 2002 1664 1669
2. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261
3. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
4. A. Bill-Axelson, L. Holmberg, and H. Garmo Radical prostatectomy or watchful waiting in early prostate cancer N Engl J Med 370 2014 932 942
5. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
6. R.M. Martin, D. Gunnell, F. Hamdy, D. Neal, A. Lane, and J. Donovan Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era J Urol 176 2006 439 449
7. I.J. Dahabreh, M. Chung, and E.M. Balk Active surveillance in men with localized prostate cancer: a systematic review Ann Intern Med 156 2012 582 590
8. M.A. Dall'Era, P.C. Albertsen, and C. Bangma Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976 983
9. J.L. Mohler, B.T. Williams, J.A. Freeman, and J. Mohler Expectant management as an option for men with stage T1c prostate cancer: a preliminary study World J Urol 15 1997 364 368
10. W.M. Chen, C.R. Yang, and Y.C. Ou Clinical outcome of patients with stage T1a prostate cancer J Chin Med Assoc 66 2003 236 240
11. M.A. Khan, H.B. Carter, and J.I. Epstein Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170 2003 2274 2278
12. M.I. Patel, D.T. DeConcini, E. Lopez-Corona, M. Ohori, T. Wheeler, and P.T. Scardino An analysis of men with clinically localized prostate cancer who deferred definitive therapy J Urol 171 2004 1520 1524
13. J. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
14. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
15. R.A. Godtman, E. Holmberg, A. Khatami, J. Stranne, and K. Hugosson Outcome following surveillance of men with screen-detected prostate cancer. Results from the Gothenburg randomised population-based prostate cancer screening trial Eur Urol Suppl 11 2012 e1094
16. E.D. Selvadurai, M. Singhera, and K. Thomas Medium-term outcomes of active surveillance for localised prostate cancer Eur Urol 64 2013 981 987
17. A. Adamy, D.S. Yee, and K. Matsushita Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
18. B.E. Ayres, B.S.I. Montgomery, and N.J. Barber The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance BJU Int 109 2012 1170 1176
19. J.J. Tosoian, B.J. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
20. B. Ercole, S.R. Marietti, J. Fine, and P.C. Albertsen Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era J Urol 180 2008 1336 1341
21. I.F. San Francisco, L. Werner, M.M. Regan, M.B. Garnick, G. Bubley, and W.C. DeWolf Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance J Urol 185 2011 471 476
22. M.S. Soloway, C.T. Soloway, A. Eldefrawy, K. Acosta, B. Kava, and M. Manoharan Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
23. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2012 597 603
24. M. Allué López, C. Allepuz Losa, A. Borque Fernando, P. Serrano Frago, P. Gil Martínez, and M. Gil Sanz Cáncer de próstata incidental: T1a-T1b. Nuestra experiencia tras observación/intervención radical y revisión de la literatura Actas Urol Esp 30 2006 749 753
25. B.D. Odom, M. Mir, and S. Hughes Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience Urology 83 2014 364 368
26. Y. Kakehi, T. Kamoto, and T. Shiraishi Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer Jpn J Clin Oncol 38 2008 122 128
27. M. Al Otaibi, P. Ross, and N. Fahmy Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance Cancer 113 2008 286 292
28. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
29. J.J. Ischia, C.Y. Pang, Y.K. Tay, C.F.D. Li Wai Suen, H.C. Aw, and M. Frydenberg Active surveillance for prostate cancer: an Australian experience BJU Int 109 2012 40 43
30. C. Hardie, C. Parker, and A. Norman Early outcomes of active surveillance for localized prostate cancer BJU Int 95 2005 956 960
31. S. Roemeling, M.J. Roobol, and S.H. de Vries Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome Eur Urol 51 2007 1244 1251
32. J. Forde, P. Daly, and S. White A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland Ir J Med Sci 183 2014 377 382
33. D. Margel, I. Nandy, T.H. Wilson, R. Castro, and N. Fleshner Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study J Urol 190 2013 2039 2046
34. V. Hernández, C. Blázquez, E. de la Peña, E. Pérez-Fernández, F. Díaz, and C. Llorente Active surveillance in low-risk prostate cancer. Patient acceptance and results Actas Urol Esp 37 2013 533 537
35. K. Hashine, H. Iio, Y. Ueno, S. Tsukimori, and I. Ninomiya Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer Int J Clin Oncol 19 2014 531 535
36. A. Descazeaud, M. Peyromaure, and A. Salin Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era Eur Urol 53 2008 355 362
37. J. Lane, J.L. Donovan, and M. Davis Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial Lancet Oncol 15 2014 1109 1118
38. P.C. Albertsen, J.A. Hanley, and G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248 1253
39. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and L.L. Egevad The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29 2005 1228
40. National Institute for Clinical Excellence. NICE clinical guideline 175. Prostate cancer: diagnosis and treatment. http://www.nice.org.uk/guidance/cg175.
41. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
42. M.S. Cookson, N.E. Fleshner, S.M. Soloway, and W.R. Fair Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications J Urol 157 1997 559 562
43. J.B. Lattouf, and F. Saad Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 90 2002 694 698
44. G.D. Grossfeld, J.J. Chang, and J.M. Broering Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database J Urol 165 2001 851 856
45. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
46. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively Int J Cancer 128 2011 2373 2381
47. G. Sölétormos, A. Semjonow, and P.E.C. Sibley Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice Clin Chem 51 2005 1342 1351
48. C. Metcalfe, K. Tilling, and M. Davis Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study Br J Cancer 101 2009 390 394
49. P.A. Ganz, J.M. Barry, and W. Burke National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer Ann Intern Med 156 2012 591 595